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Purpose. The aim of this work was to develop speciﬁc radiopharmaceutical and to evaluate its eﬃcacy in human to detect and
locate the tubercular lesion. Materials and Methods. 99mTc-Ethambutol (EMB) was produced by direct labeling method. In vitro
andinvivobiologicalstudiesandanimalexperimentsweredone.PhaseIClinicaltrialwasperformed.Asperplan,2normalhuman
subjectsforbiodistributionstudiesandfourteenpatients(8malesand6females;agerangeof25–50,withonepatientaged12years
as an exception) were chosen for clinical trial. Whole body scan and spots were acquired at 1 hour and 4 hour. Angiography, blood
pool, and 24-hours spot images of the infected areas were also acquired. Result. Radiolabeling yielded >85% of labeled complex.
In vitro and in vivo biological studies and animal experiments indicated 99mTc-EMB as a speciﬁc tuberculosis imaging agent. The
biodistribution study in normal human subjects suggested stability of 99mTc-EMB, with main excretory pathways being renal and
hepatobiliary, which appeared to be similar to the known behavior of unlabeled EMB. No adverse reactions were observed. 99mTc-
EMB got localized in pulmonary and bone tubercular lesions. Scintigrams of 99mTc-EMB and 99mTc-Ciproﬂoxacin were compared
at diﬀerent time intervals. Conclusion. The present study states that developed 99mTc-EMBhas high potential toqualify as a speciﬁc
tuberculosis imaging radiopharmaceutical and is safe for human use.
1.Introduction
Tuberculosis (TB) is dreaded infectious aﬀecting almost
every organ of the body and still it is one of the major
health hazards with sophisticated research, high-tech drug
design, and various diagnostic modalities. Rapid and accu-
rate diagnosis of infected patients is a cornerstone of the
global tuberculosis control strategies. Microscopic exami-
nation, Bacterial culture, Radiometric methods (BACTEC,
MGIT, etc.), Chromatographic procedures, Immunodiag-
nostic modalities (ELISA, RIA, SAFA etc), Molecular diag-
nostic tools (PCR, RFLP, LCR, etc.), and Radiological and
Imaging modalities have played very important roles in
diagnosis of tubercular infection. Despite several advantages,
these modalities have certain limitations in diagnosis of TB.
Radionuclide emission-based nuclear medicine modality is
a noninvasive technique, which is a quick, sensitive, and
speciﬁc method to detect as well as locate the lesion at
any anatomical site at early stage of the disease. A wide
variety of radiopharmaceuticals are used now a day for
the diagnosis of infection and inﬂammation. Ga-67 citrate
was one of the ﬁrst radiopharmaceuticals developed for
infection and inﬂammation [1] imaging. Ga-67 citrate was
used for detection of pulmonary and extrapulmonary TB
but it had limitation of being nonspeciﬁc and incapable of
diﬀerentiating between infection and inﬂammation. Non-
speciﬁc SPECT agents like
99mTc-ethylene cysteine dimer
havebeenusedfordiagnosisoftubercularmeningitis.
99mTc-
Tetrofosmin [2], FDG-PET [3], and
99mTc-MIBI [4]w e r e
used for showed concentration in tubercular lesion by means
of nonspeciﬁc uptake but these radiotracers had limited
clinical success.
99mTc-Ciproﬂoxacin (Infecton) possesses2 Tuberculosis Research and Treatment
many properties to be evaluated as novel infection imaging
agent [5].
99mTc-Ciproﬂoxacin was nonspeciﬁc and showed
low sensitivity in nonbony for tubercular lesion. In view
of these limitations and disadvantages, a suitable ligand,
that is, speciﬁc ﬁrst line antitubercular drug Ethambutol
(EMB) [6] was chosen for detection as well as localization
of the lesion using nuclear medicine modality. EMB was
radiolabeled with Tc-99m. High labeling eﬃciency (>85%),
in vitro, in vivo stability, biodistribution, and pharmacoki-
netic parameters were consistent with the original drug [7]
which suggested that
99mT c - E M Bw a ss a f ef o rd i a g n o s t i c
use. The objectives of the work was (a) to prepare and
characterize
99mTc-EMB (b) to compare data obtained with
99mTc-EMB in living systems with the known behavior of its
unlabeledform,and(c)toconductclinicaltrialsandevaluate
its eﬃcacy in human to detect and locate the tubercular
lesion.
2.MaterialsandMethods
2.1. Radiocomplexation of EMB. Ethambutol was labeled
with
99mTc. Radiocomplexation was standardized [6].
Brieﬂy, 2mg of ethambutol (sigma chemicals, USA) was
taken in a vial and was dissolved in 1ml of 0.015MNaCl2
solution. To the ethambutol solution, 200μl (400μg) of
2mg/ml solution of stannous tartarate dissolved in sterile
water for the injection (to increase shelf life of the reducing
agent) was added and mixed well. 50μgo fρ-amino benzoic
acid was added as a stabilizer to the solution. To it, 75–
400MBq of freshly eluted
99mTc was added using sterilized
ﬁneneedlesyringe.Themixturewasswirledandwasallowed
to react for 15 minutes. Radiochemical purity was deter-
mined by ITLC method.
99mTc-EMB was characterized by
Infrared (IR) and Mass spectral (MS) studies. In vivo and in
vitro experiments were done. Good Manufacturing Practice
measures were followed strictly, using fresh chemicals and
sterile laboratory ware.
2.2. In Vitro and In Vivo studies. In vitro serum and blood
stabilitystudiesof
99mTc-EMBwerecarriedout.
99mTc-EMB
was mixed with serum and blood separately in vials (in
triplicate), and samples were taken out from the vials at 1
hour, 4 hours, and 24 hours and assessed by ITLC system.
Biodistribution and pharmacokinetic studies were done in
Balb/c mice and New Zealand white rabbits, respectively.
Parameters like plasma clearance, Plasma protein binding,
T1/2, and volume of distribution (VD) were calculated
and compared with the known values of the unlabeled
EMB [7]. All tests were done in triplicate. The results
were compared quantitatively and qualitatively. Experiments
were carried out in compliance with the relevant national
laws relating to the conduct of animal experimentation.
Biological activity of
99mTc-EMB was evaluated by in
vitro pharmacological studies, that is, Minimum inhibitory
concentration (MIC) experiment, drug uptake studies, and
colony forming assay (CFU assay). Scintigraphy was done
in New Zealand white rabbit to evaluate biodistribution of
99mTc-EMB.
2.3. Human Studies
2.3.1. Study Design. The stated objectives of the human
trial were (a) to conﬁrm safety aspects of the new radio-
pharmaceutical in humans, (b) to check consistency and
uniformityofbehaviorofthetracerinhumans,(c)tosuggest
a practical study protocol, and (d) to study its uptake in
known active and inactive tubercular lesions. As per plan,
two normal human subjects and fourteen patients (with
freshly diagnosed and dormant lesion) were chosen for the
study.
2.3.2. Patient Selection. Institutional Ethical Committee per-
mission in accordance with the guidelines provided by
Indian Council of Medical Research (ICMR) and Helsinki
Declaration of 1975, as revised in 2000 and patient’s consent
was taken prior to initiation of the human studies. The
two subjects were healthy adult male volunteers without any
knowndisease.TheotherFourteenwereambulatorypatients
with proven tuberculosis with known sites of infection.
Four had freshly diagnosed sensitive (2) and resistant (2)
pulmonarytuberculosis(diagnosedbysputumpositivityand
sites of infection identiﬁed by x-ray chest), eight patients
had bone tuberculosis lesions (proof of infection and site
identiﬁcation by radiology and serology in clinical context),
and two had old dormant bony lesions. A comparative
study of
99mTc-Ciproﬂoxacin and
99mTc-EMB was done in
a patient having lesion in acetabulum. Only those patients
were recruited for the study that were not overtly sick
and did not suﬀer from any other disease or disorder.
Details of patients (age/sex) and their clinical status are
shown in Table 1. The patients were admitted for at least
a day for observation for precaution, though no detailed
investigations were done for creating detailed toxicity data
proﬁle of
99mTc-EMB.
2.3.3.ScintigraphyProcedure. Thepatientswerenotrequired
to fast before scintigraphy. 370MBq of freshly prepared
99mTc-EMB was injected intravenously as a slow bolus in
adults. Angiography, blood pool phase, and spot acquisitions
of sites known to harbor tubercular lesions were taken at
1 hour, 4 hours, and 24 hours in the best view using a
standard dual-head Gamma Camera. Acquisition time was
kept ﬂexible and was depended upon count density of the
ﬁeld. Whole Body acquisitions were taken at 1 and 4 hours
at slow speed (10–15cm/min). Anterior and posterior views
of abdomen and chest were acquired to aid biodistribution
assessment. SPECT data was acquired in two cases with bony
lesions at 4–6 hours. The patients were critically observed
for any signs and symptoms and any deviation in the vitals
throughout the day.
2.3.4. Results. The radiochemical purity of
99mTc-EMB was
found to be >85%. In vitro stability study of
99mTc-EMB in
blood and serum showed that only 3%-4% of technetium
leached out from the complex till 24 hours of incubation.
IR spectra of unlabeled EMB gave peak at the region of
∼ 3300–2900 cm-1 d u et oN Ha n dO Hs t r e t c hi nE M BTuberculosis Research and Treatment 3
Table 1: Clinical details of patients and result of 99mTc-EMB scintigraphy.
Sex/Age Clinical diagnosis Site of lesion Treatment history Outcome
Male/40 Pulmonary TB Lungs Active pulmonary tuberculosis True positive
Male/45 Pulmonary TB Lungs Active pulmonary tuberculosis True positive
Male/50 Resistant
pulmonary TB Lungs Active resistant pulmonary
tuberculosis True positive
Female/42 Resistant
Pulmonary TB Lungs Active resistant pulmonary
tuberculosis True positive
Female/27 Bone TB Spine 1. Old treated case of Pott’s spine
2. local tenderness present True negative
Male/43 Bone TB Spine Old treated case of Pott’s spine. True negative
Male/30 Bone TB Ankle Tuberculosis of ankle True positive
Female/36 Bone TB Ankle Tuberculosis of ankle, active on
MRI clinically True positive
Male/34 Bone TB Spine
1. Carries retropharyngeal
abscesses.
2. MRI carries yellow marrow
replacement in vertebral bodies.
True positive
Female/40 Bone TB Ankle Tuberculosis of ankle, positive in
4th metatarsal of the right foot. True positive
Female/35 Bone TB Lymph nodes in
the neck Tuberculosis in throat No ATT True Positive
Male/32 Bone TB Spine A case of cervical TB True positive
Male/51 Bone TB Spine A case of Pott’s spine with local
tenderness True positive
Female/12 Bone TB Spine and
Acetabulum
1. Active Pott’s spine
2. Large psoas abscess
3. Unsuspected pelvic infection later
conﬁrmed by MRI
True positive
Table 2: Biodistribution data of 99mTc-EMB in Balb/c mice.
The mice were administered 40KBq of 99mTc-INH, and the
radioactivity in diﬀerent organs was measured at 1hr, 4hrs, and
24hrs, respectively. each value is the mean±SD of three mice and
expressed as percentage administered dose per gram organ.
Organ/Tissue 1 hour 4 hours 24 hours
Blood 2.0±0.03 1.3±0.19 0.8±0.02
Heart 0.73±0.21 0.54±0.07 0.36±0.6
Lungs 2.1±0.18 1.88±0.3 1.05±0.04
Liver 5.5±0.5 7.0±03 . 8 3 ±0.21
Spleen 1.41±0.09 1.78±0.43 1.04±0.02
Intestine 6.21±0.4 6.99±0.17 2.09±0.03
Kidney 10.3±0.42 11.35±0.32 2.02±0.04
Muscle 1.6 ±0.2 1.0±0.2 1.68±1.1
Bone 1.08±0.28 0.88±10 . 6 4 ±0.05
Brain 0.165±0.06 0.07±0.19 0.06±0.2
Stomach 1.01±0.31 0.8±11 . 0 ±0.3
structure. The absence of peak in
99mTc-EMB indicated that
99mTc binds to these groups by protonation. Mass spectra
of unlabeled EMB showed peak at 102.5 and 116.2 due
to NH and OH groups and the absence of these peaks in
Table 3: Comparison of pharmacokinetic parameters of 99mTc-
EMB and unlabeled EMB.
99mTc-EMB Unlabeled
99mTc-EMB
T1/2 =9.5 hours T1/2 =10–15 hours
Vd =2.8L/Kg Vd =3.1L/Kg
Cl=16.5ml/hr Cl=15–20ml/hr
Plasma protein binding=60% Plasma protein
binding=10%–40%
Where, T1/2 is half-life, Vd is volume of distribution, and Cl is clearance.
99mTc-EMB indicated that
99mTc binds to NH and OH
groups. Organ biodistribution done in Balb/c mice showed
maximum accumulation of
99mTc-EMB in kidneys followed
by liver and intestine shown in Table 2 [8].
Various pharmacokinetic parameters of
99mTc-EMB
showed similarity with its unlabeled counterpart shown in
Table 3. Plasma protein binding studies showed that ∼85%
of
99mTc-EMB was bound to plasma protein till 24 hours.
In vitro pharmacological studies indicated the retention of
biological activity of EMB after radiocomplexation. Scintig-
raphy done in New Zealand white rabbits at 1 hour and
4 hours postinjection showed high tracer uptake in the
kidneys and liver. Intestinal activity was evident signifying4 Tuberculosis Research and Treatment
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Figure 1: Whole body scan of human (healthy volunteer) showing biodistribution of
99mTc-EMB in human at 1 hour anterior and posterior
and 4 hours anterior and posterior postinjection of radiotracer.
gall bladder excretion. No activity was seen in the stomach
region [6].
2.3.5. Scintigraphy and Patient Studies. Sixteen human sub-
jects were available for assessing safety aspects of
99mTc-
EMB. Two healthy individuals were chosen for studying
biodistribution of
99mTc-EMB and fourteen patients for
studying lesion uptake pattern. No adverse eﬀects or allergic
reactions were noted in the patients in the immediate
and acute periods following tracer injection. The vitals
were checked periodically, which remained stable. No prob-
lem was reported in the patients kept under observation
overnight. Since the drug molecule and the reducing agent
(stannous tartarate) are well-known clinical entities, used
in complex formation are minute diagnostic doses; detailed
toxicity data were not created.
2.3.6. Human Biodistribution of
99mTc-EMB. Whole-body
scans taken at 1 and 4 hours and spots at 24 hours were
analyzed qualitatively. The
99mTc-EMB got well distributed
in the body compartments by 1 hour of postinjection
(except blood-brain barrier which was never breached), with
marginally higher concentration in blood as shown by faint
cardiac and great veins visualization. Hepatic accumulation
of radioactivity appeared to increase slowly with time, which
probably reduced after 4 hours. Radioactivity was visualized
in intestine before 4 hours of postinjection of
99mTc-EMB
with frequent gall-bladder visualization. Signiﬁcant urinary
activity was seen by 1 hour and kidneys were the main
excretory organs. Signiﬁcant renal cortex retention of
99mTc-
EMB was also a constant ﬁnding (Figure 1). Uptake of
99mTc-EMB was fairly uniform in both lungs and appeared
to buildup with time, probably stabilizing by 4 hours, which
reduced at 24 hours. No uptake of
99mTc-EMB was seen inTuberculosis Research and Treatment 5
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Figure 2: Whole body scan of human (healthy volunteer) showing biodistribution of
99mTc-EMB in human at 1 hour anterior and posterior
and 4 hours anterior and posterior (postinjection of radiotracer and lesion in ankle (Bone TB).
dormant cases. There was no bone or bone marrow activity.
Interestingly, no activity was observed in epiphysis, stomach,
and thyroid (Figure 1).
2.3.7. Study Protocol and Lesion Uptake. At o t a lo ff o u r t e e n
subjects were identiﬁed as infected cases in prescan diagnosis
(Table 1). Four had lesion in lungs (soft-tissue) and ten had
bone tubercular lesions in peripheral skeleton, two being
dormant ones. Soft-tissue lesions infected with tuberculosis
were gained in radioactivity with time. No radioactivity was
observed in dormant cases. A majority of soft-tissue lesions
were visualized after 4 hours and one was visualized only
at 24 hours postinjection of
99mTc-EMB. Interestingly, an
unsuspected pulmonary lesion was discovered on one scan
that was later conﬁrmed on a fresh X-ray chest. SPECT
acquisitions done on dormant pulmonary lesions seen in
planer view in two patients were of poor quality and failed
to locate the lesion with any deﬁnition or contrast. Bone
tubercular lesions were well visualized even on one-hour
scan, and appeared to gain little activity (Figure 2). Thus
there was a very slow ratio enhancement of radioactivity
with time (Figure 3). In general,
99mTc-EMB uptakes in
bone lesions were higher quantitatively as compared to
the lung lesions, which required higher count collection
and delayed acquisition for proper visualization. Preferential
localization of
99mTc-EMB was seen in sensitive (Figure 4)
and resistant (Figure 5) pulmonary lesion. The comparative6 Tuberculosis Research and Treatment
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Figure 3: SPECT and scintigrams of patient, showing preferential localization of radiotracer in the ankle lesion after 1hr and 4 hours
postinjection of 370MBq of
99mTc-EMB.
1hr
(a)
4hrs
(b)
Figure 4: Scintigrams of patient, showing preferential localization of radiotracer in the lung lesion after 1 hour and 4 hours postinjection of
370MBq of
99mTc-EMB.Tuberculosis Research and Treatment 7
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Figure 5: Scintigrams of human showing preferential localization of radiotracer in the resistant lung lesion after 1, 4, and 24 hours
postinjection of 370MBq of
99mTc-EMB.
study of
99mTc-Ciproﬂoxacin and
99mTc-EMB showed that
99mTc-Ciproﬂoxacin got washed away at 4 hours and
99mTc-
EMB was observed in the lesion till 24 hours postinjection
(Figure 6).
3. Discussion
Each vial contains 2mg/ml of EMB and 200μg of stannous
tartarate. Both have known safety proﬁle. Adverse eﬀects
of EMB are rare and dose dependent. Optic neuropathy or
cardio-hepatotoxicity occurs very infrequently after several
months of therapeutics. The drug is freely given in pediatric
age group of patients. The diagnostic dose administered
to the subjects was therefore inconsequential. In clinical
context,itwasconsideredasasaferadiopharmaceutical,even
in children though it should be used with abundant caution
in younger age group.
The route of excretion of
99mTc-EMB is through urine,
mostly in its native form. A small percentage is metabolized
in liver and the end products were excreted though kidneys.
Very little excretion took place through the biliary pathway.
99mTc-EMB is not known to selectively collect in or interact
with reticuloendothelial system and bone [9]. No accumu-
lation of the tracer in RES and bone was an important neg-
a t i v eo b s e r v a t i o nb e c a u s et h ef a c tm a yb ea d v a n t a g e o u si n
improving accuracy of detection of bony tubercular lesions
with the tracer. Whole body biodistribution of
99mTc-EMB
was consistent with these pharmacokinetic characteristics
of ethambutol, including the tendency to concentrate in
lung parenchyma. Plasma protein binding, blood clearance,
volume of distribution, and half-life of
99mTc-EMB(Table 3)
were similar to unlabeled EMB [7].
Accumulation of
99mTc-EMB in lung parenchyma (sim-
ilar to the native drug) was a distinct advantage because8 Tuberculosis Research and Treatment
99mTc-ciproﬂoxacin
1hr (ant)
(a)
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Figure 6:Scintigramshowingcomparativestudyofpreferentiallocalizationof
99mTc-Ciproﬂoxacinand
99mTc-EMBinapatientafter1hour
(Figures 1 and 2, resp.) and 4 hours (Figures 3 and 4, resp.) postinjection of 370MBq of
99mTc-Ciproﬂoxacin and
99mTc-EMB, respectively.
poor bacterial count, low metabolic status (of mycobac-
terium), and ﬁbrotic encapsulation of tubercular lesions in
the lungs result in relatively poor sensitivity of any other
99mTc labeled radiotracer.
99mTc-EMB would be in an
advantageous position compared to other tracers because a
higher physiologic concentration of the radiolabeled drug
in the lung parenchyma may translate into higher uptake
by mycobacterium, and therefore into higher sensitivity of
detection. For this reason, delayed imaging till 24 hours
appeared essential for imaging. Retention of
99mTc-EMB in
the lesion till 24 hours indicated that
99mTc-EMB was more
speciﬁc radiopharmaceutical than
99mTc-Ciproﬂxacin for
tubercular lesion imaging as
99mTc-Ciproﬂxacin got washed
away at 4 hours of postinjetion.
99mTc-EMB was used in humans for tubercular imaging.
The purpose of this preliminary human study was to
evaluate feasibility of using the
99mTc-EMB in human
tubercularscintigraphy.Itsuggestedthat
99mTc-EMBdetects
and locates active sensitive as well as resistant lesions
by accumulating in the lesion in rising pattern over
time.
4. Conclusion
The mycobacterial lesion uptake study carried out so far in
humans suggested that
99mTc-EMB is speciﬁc and sensitive
radiopharmaceutical for sensitive as well as resistant tuber-
cular lesion detection and localization.
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